EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials

Louise Kofod, Madicken Pedersen, Mette Andersen, Emilie Christensen, Pernille Pedersen, Hiva Alipour, Pia Egerup, Ole Bjarne Christiansen, Ulrik Schiøler Kesmodel

Journal of Reproductive Immunology · 2025-08 · 170 · 104541

DOI: 10.1016/j.jri.2025.104541 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Reproductive Immunology, 2025-08. Verfasst von Louise Kofod und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital, Reberbansgade 15, Aalb…. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Abortion, Habitual. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrent pregnancy loss (RPL) affects 1-2 % of fertile couples, with immunological factors increasingly implicated in unexplained cases. Currently, no convincing treatment exists. Intravenous immunoglobulin (IVIg) has been explored as a potential treatment, but results have been inconsistent. This study evaluates whether IVIg affects live birth rates in women with RPL in subsequent pregnancies. We searched PubMed, Embase, and Cochrane libraries for relevant randomized controlled trials up to March 20, 2023, and contacted authors for individual patient data. Trials involving women with two or more consecutive pregnancy losses who received IVIg or placebo before or during the first trimester were included. Primary outcomes were live birth and clinical pregnancy rates, with secondary outcomes including pregnancy loss rate, side effects, adverse events, and perinatal outcomes. Risk of bias and certainty of evidence (GRADE) were evaluated. Ten studies involving 662 women were included. The intention-to-treat analysis showed no significant difference in live birth rates between IVIg and placebo groups (RR: 1.02, 95 % CI: 0.86-1.22, p = 0.78, GRADE: moderate). However, per-protocol analysis indicated an increased live birth rate with IVIg (RR: 1.23, 95 % CI: 1.00-1.50, GRADE: low). Live birth rates after IVIg improved with the number of previous losses, especially in patients with ≥ 6 losses (RR: 5.26 (1.58-17.53)). While IVIg therapy did not show a significant improvement in live birth rates overall, future research should focus on identifying specific patient subgroups, such as those with multiple prior losses, who may benefit most from this treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousAbortion, HabitualHumansFemalePregnancyRandomized Controlled Trials as TopicLive Birth

Stichwörter der Autor:innen

Habitual abortionImmunoglobulinsLive birthMeta-analysisSystematic review

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Center for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital, Reberbansgade 15, Aalborg 9000, Denmark. Electronic address: louise.kofod@rn.dk.
  • Department of Obstetrics and Gynaecology, Aalborg University Hospital, Reberbansgade 15, Aalborg 9000, Denmark.
  • Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Selma Lagerløfs Vej 249, Gistrup 9260, Denmark.
  • Copenhagen University Hospital Hvidovre, Department of Obstetrics and Gynecology, Kettegård Alle 36, Hvidovre 2650, Denmark.
  • Center for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital, Reberbansgade 15, Aalborg 9000, Denmark.
  • Department of Obstetrics and Gynaecology, Aalborg University Hospital, Reberbansgade 15, Aalborg 9000, Denmark and Department of Clinical Medicine, Aalborg University, Selma Lagerløfs 249, Gistrup 9260, Denmark.

Zitieren

APA

Kofod, L., Pedersen, M., Andersen, M., Christensen, E., Pedersen, P., Alipour, H., Egerup, P., Christiansen, O. B., & Kesmodel, U. S. (2025). Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials. Journal of Reproductive Immunology, 170, 104541. https://doi.org/10.1016/j.jri.2025.104541

Vancouver

Kofod L, Pedersen M, Andersen M, Christensen E, Pedersen P, Alipour H, et al. Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials. Journal of Reproductive Immunology. 2025;170:104541. doi:10.1016/j.jri.2025.104541

BibTeX
@article{Kofod2025,
  author = {Kofod, Louise and Pedersen, Madicken and Andersen, Mette and Christensen, Emilie and Pedersen, Pernille and Alipour, Hiva and Egerup, Pia and Christiansen, Ole Bjarne and Kesmodel, Ulrik Schiøler},
  title = {Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials},
  journal = {Journal of Reproductive Immunology},
  year = {2025},
  volume = {170},
  pages = {104541},
  doi = {10.1016/j.jri.2025.104541}
}
Kostenlos starten →